Vincerx Pharma, Inc. (VINC)

NASDAQ: VINC · IEX Real-Time Price · USD
-0.037 (-5.41%)
Nov 28, 2023, 4:00 PM EST - Market closed

Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.

It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.

The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies.

Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Vincerx Pharma, Inc.
Vincerx Pharma logo
Country United States
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Dr. Ahmed M. Hamdy M.D.

Contact Details

260 Sheridan Avenue, Suite 400
Palo Alto, California 94306
United States
Phone 650-800-6676

Stock Details

Ticker Symbol VINC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001796129
CUSIP Number 92731L106
ISIN Number US92731L1061
Employer ID 83-3197402
SIC Code 2834

Key Executives

Name Position
Dr. Ahmed M. Hamdy M.D. Founder, Chairman and Chief Executive Officer
Tom C. Thomas J.D. Founder, General Counsel and Chief Legal Officer
Dr. Raquel E. Izumi Ph.D. Founder, President, Chief Operating Officer, Secretary and Director
Dr. John C. Byrd M.D. Founder and Chairman of Scientific Advisory Board
Alexander A. Seelenberger M.B.A., MBA Chief Financial Officer
Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer
Melissa Merrick SPHR Senior Director of People and Culture
Dr. David Nganele M.B.A., Ph.D. Head of Early Development
Dr. Beatrix Stelte-Ludwig Ph.D. Executive Chief Development Officer

Latest SEC Filings

Date Type Title
Nov 14, 2023 10-Q Quarterly Report
Nov 14, 2023 8-K Current Report
Sep 15, 2023 8-K Current Report
Aug 7, 2023 8-K Current Report
Aug 7, 2023 10-Q Quarterly Report
Jun 20, 2023 8-K Current Report
May 30, 2023 8-K Current Report
May 11, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
Apr 12, 2023 ARS Filing